Swedish cancer diagnostics company INIFY Laboratories AB (Euronext Growth Oslo:INIFY) announced on Wednesday that it is expanding its operations into the United Kingdom.

The company plans to invest approximately SEK150m to establish a new laboratory in the UK, aiming to address challenges in prostate cancer care.

The UK market for cancer diagnostics is estimated to be significantly larger than Sweden's, with around 120,000 patients annually requiring prostate cancer diagnosis. Inify believes its technology can improve response times and quality of care in the UK healthcare system.

Initial samples from the UK will be handled by Inify's Swedish laboratory during the establishment phase. The company expects the new UK laboratory to be operational in early 2026.

In addition to prostate cancer, Inify plans to offer diagnostics for gastrointestinal diseases, a market with a significantly larger volume of samples and a wider range of conditions.

(EUR1=SEK11.42)